Skip to main content
Clinical Trials/CTRI/2018/03/012603
CTRI/2018/03/012603
Not yet recruiting
未知

Study of effect of teneligliptin versus glimepiride on tumor necrosis factor alpha (TNF- α) and high sensitivity C- reactive protein (hs-CRP) in type 2 diabetes mellitus patients treated with metformin. - TNF/CRP

MALEHA BUT0 sites0 target enrollmentTBD

Overview

Phase
未知
Intervention
Not specified
Conditions
Not specified
Sponsor
MALEHA BUT
Status
Not yet recruiting
Last Updated
4 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
4 years ago
Study Type
Interventional

Investigators

Sponsor
MALEHA BUT

Eligibility Criteria

Inclusion Criteria

  • 1\.Body mass index (BMI) more than 25 kg/m2
  • 2\.All type 2 DM patients with a history of diabetes for the past 1 to 3 years
  • 3\.Type 2 diabetics with fasting blood sugar more than 126mg/dl and glycosylated hemoglobin (HbA1c) between 7\.0 to 10\.0 % before enrollment.
  • 4\.All type 2 DM patients, who are on stable dose of metformin (up to 2500mg/day) for the past 12 weeks.
  • 5\.All patients naive to teneligliptin and glimepiride.
  • 6\.All patients willing to give consent to participate in the study.

Exclusion Criteria

  • 1\.Uncontrolled hypertension (systolic BP more than or equal to 180 mmHg and diastolic BP more than or equal to 100 mmHg)
  • 2\.Uncontrolled diabetes (HbA1c more than or equal to 10\.0 %).
  • 3\.Patientâ??s having serum creatinine (SCr) levels more than or equal to 2mg/dL.
  • 4\.Patients with hepatic impairment (AST and ALT levels more than or equal to 3 times the upper limit).
  • 5\.Serum triglycerides more than or equal to 500mg/dl.
  • 6\.Pregnant females and lactating mothers
  • 7\.History of hypersensitivity to study drugs.
  • 8\.History of taking non steroidal anti\-inflammatory drugs or any other drugs that affect the study parameters.
  • 9\.Patients on any other herbal and dietary supplements.

Outcomes

Primary Outcomes

Not specified

Similar Trials